Related Experiment Video
Updated: Jun 3, 2025
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Advancing siRNA Therapeutics targeting MCT-4: A Multifaceted approach integrating Arithmetical Designing, Screening,
Aadya Raj Pandey1, Anurag Kumar1, Neeraj Kumar Shrivastava1
1Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow 226025, India.
Abstract:
Monocarboxylate transporter 4 (MCT-4) is involved in various metabolic processes which are crucial in maintaining cellular pH and energy metabolism, and thus influence the tumor microenvironment. The study is aimed to rationally design effective Small interfering RNA (siRNA) that can silence MCT-4. We utilized a comprehensive workflow integrating multiple tools such as siDirect version 2.0, Oligowalk and i-score designer, to evaluate sequence features and predict target site accessibility, Guanine-Cytosine (GC) content and thermodynamic stability. Five (M1, M2, M3, M4 and M5) siRNAs sequences were retrived and subjected to further scrutiny on the account of off-target elimation, sequence conservation, secondary structure formation, and thermodynamic properties. The M1 demonstrated off targets and the M2 sequence showed secondry conformation and therefore M3, M4 and M5 were considered for further evaluation. Additionally, molecular docking and simulations (50 ns) were conducted with human Argonaute 2 protein (h-Arg-2). The post- molecular dynamics (MD) analysis revealed M4 (5'UUGAAGAAGACACUGACGG3') as a most appropriate siRNA candidate agsint MCT-4 on the basis of Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), and H-Bond results. The Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) analysis was also performed to further validate the selected siRNA candidates, which further affirmed M4 (5'UUGAAGAAGACACUGACGG3') as an potential candidate for future in-vitro and in-vivo evaluation.
Insights
Researchers designed small interfering RNA (siRNA) to silence monocarboxylate transporter 4 (MCT-4), a key factor in cellular pH and tumor microenvironments. Molecular simulations identified M4 (5'UUGAAGAAGACACUGACGG3') as the most promising siRNA candidate for further testing.
Area of Science:
- Molecular biology
- Bioinformatics
- Cancer research
Background:
- Monocarboxylate transporter 4 (MCT-4) plays a critical role in cellular pH regulation and energy metabolism.
- MCT-4 influences the tumor microenvironment, making it a potential therapeutic target.
- Effective small interfering RNA (siRNA) design is crucial for gene silencing applications.
Purpose of the Study:
- To rationally design effective siRNA sequences for silencing MCT-4.
- To identify the most stable and specific siRNA candidate through computational analysis.
Main Methods:
- Utilized a computational workflow integrating siDirect, Oligowalk, and i-score designer for siRNA evaluation.
- Assessed sequence features including target accessibility, GC content, and thermodynamic stability.
- Performed molecular docking and 50 ns molecular dynamics simulations with human Argonaute 2 protein (h-Arg-2).
Main Results:
- Five potential siRNA sequences (M1-M5) were initially identified.
- M1 and M2 were excluded due to off-target effects and secondary structure formation, respectively.
- Molecular dynamics and MMPBSA analyses identified M4 (5'UUGAAGAAGACACUGACGG3') as the optimal candidate based on stability and binding interactions with h-Arg-2.
Conclusions:
- The rationally designed M4 siRNA sequence demonstrates significant potential for MCT-4 gene silencing.
- Computational methods provide a robust framework for identifying effective siRNA candidates.
- M4 warrants further in vitro and in vivo evaluation for therapeutic applications targeting MCT-4.
![Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F59557.jpg&w=3840&q=50)
